Navigation Links
ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
Date:9/30/2008

SYDNEY, Australia, Sept. 30 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that a marketing application for the mucus clearing agent, Bronchitol, has been submitted to the Therapeutic Goods Administration (TGA) division of the Australian Government. If approved, Pharmaxis will be authorized to market Bronchitol in Australia for the treatment of bronchiectasis.

The application is based on a multicentre Phase 3 clinical trial involving more than 360 subjects which evaluated the safety and efficacy of Bronchitol for inhalation in subjects with bronchiectasis. All of the primary efficacy end points were positive and statistically significant, and Bronchitol was shown to be well tolerated with no serious adverse events attributed to treatment.

After being accepted for evaluation, the TGA has 255 working days to review the application lodged by Pharmaxis.

There is currently no approved medication that specifically targets mucus clearance for people suffering from bronchiectasis.

Alan Robertson, Pharmaxis chief executive officer said: "We are delighted to announce this major milestone for Pharmaxis and believe this is an important development for people living with the incurable lung condition bronchiectasis. Pharmaxis is dedicated to the development of safe and effective treatments for airway diseases, and we continue to work closely with regulatory authorities worldwide to bring Bronchitol to patients as quickly as possible."

It is estimated that more than 600,000 people in the major pharmaceutical markets suffer from bronchiectasis and Pharmaxis expects Bronchitol to be the first targeted medication for this patient group in 20 years, addressing an important medical need. In Australia, it is believed that more than 18,000 people live with bronchiectasis and over 70% are moderately or severely incapacitated by their condition.

Bronchitol is also under development
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New Data Support Role for Monitoring of Cell-Mediated Immunity in Adult Patients Following Renal Transplantation
2. New Data Support Earlier Suggested Guidance for Levels of Cell-Mediated Immunity in Pediatric Liver Transplant Patients
3. New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option
4. HealthMedia and Aetna to Study Online Insomnia and Depression Interventions
5. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
6. Penn State Hershey Transplant Program Uses Assay to Monitor Cell-Mediated Immunity
7. New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery
8. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
9. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
10. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
11. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 Aethlon Medical, Inc. ... address infectious diseases and cancer, today announced that ... to present a corporate overview at the 27th Annual ... Hotel in Laguna Niguel, California . ... ( http://www.roth.com/main/page.aspx?PageID=7207 ). A live webcast of ...
(Date:3/4/2015)...  Kannalife Sciences, Inc. ("Kannalife") announces that Dr. ... Board to assist the Company in the advancement of ... cannabinoid therapeutics for the treatment of Chronic Traumatic Encephalopathy ... conducting the full autopsy of Mike Webster , ... Pittsburgh Steelers. It was through his examination of ...
(Date:3/4/2015)... March 4, 2015  Heska Corporation (Nasdaq: ... You to Join Its Fourth Quarter and Year End ... 2015 @ 9:00 a.m. (MST) / 11:00 a.m. (EST)Where: ... 2014 Earnings Call link on the front page of ... to the web at the address above.  Alternatively, you ...
Breaking Medicine Technology:Aethlon Medical to Present at the 27th Annual ROTH Conference 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 3Webcast Alert: Heska Announces Fourth Quarter and Year End 2014 Earnings Conference Call Webcast 2
... /PRNewswire-FirstCall/ -- Kosan,Biosciences Incorporated announced data will be ... its Hsp90,inhibitor, epothilone and nuclear export inhibitor programs, ... for Cancer Research,(AACR), being held in Los Angeles, ... programs are as follows. The,location for all poster ...
... April 10, 2007--In a study appearing in the ... by the,National Institutes of Healths National Institute of ... a,connection between a specific gene and the inflammatory ... of autoimmune,diseases. , Vitiligo is a chronic condition ...
Cached Medicine Technology:Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 2Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 3Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 2Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 3
(Date:3/4/2015)... (PRWEB) March 05, 2015 The ... a value of $5,632.8 million by 2019, at ... of 2014 to 2019. , Browse through the ... analysis of industry trends and segments, with the ... , Phthalic Anhydride (PA) is a derivative ...
(Date:3/4/2015)... 2015 Dr. Christopher Asandra, M.D., Founder ... today lamented the FDA’s recent decision to issue ... He argued that FDA’s conclusions are not supported by ... suffer from testosterone deficiency. , “The FDA appears to ... replacement therapy,” said Dr. Asandra. “There is not nearly ...
(Date:3/4/2015)... 04, 2015 FDA’s New Inspection Approach:, ... Webinar**, March 24, 2015 — 1:30 p.m. – 3:00 ... know within four hours of an inspection whether a ... on their “good” list, they’ll merely ask for reassurance ... is on the “bad” list, the manufacturer must get ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Smokers across ... marketing campaign called 'We Love Smokers' from Aqua-Tine, the ... tobacco. , "It’s important to establish a clear ... to it. Our idea, 'We Love Smokers' elevates the ... of view. We created a bold tone of voice ...
(Date:3/4/2015)... March 04, 2015 More than a ... risks potentially associated with low testosterone treatments ( http://www.testosteronelawsuithub.com/ ... that it will now require manufacturers to warn patients ... for heart attacks and strokes. In a Drug ... also stated that it was requiring testosterone manufacturers to ...
Breaking Medicine News(10 mins):Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 2Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 3Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 2Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4
... HealthDay Reporter , FRIDAY, June 25 (HealthDay News) -- At ... her back and leg. An Army captain, helicopter pilot and ... But as her Iraq deployment continued, the pain ... stabbed. She could hardly sit, stand or walk, let alone ...
... A mechanism that regulates stem-cell differentiation in mice ... degenerative disease in humans, according to a Penn ... involved manipulating a protein called STAT3 that signals ... a specialized type of cell or self-renew and ...
... the Robert Wood Johnson Foundation have awarded 10 ... to contribute to the field of public health ... receive $1,000 for registration and travel to attend ... Group Annual Meeting, June 27-June 30, 2010, in ...
... SALT LAKE CITY Using an experimental mouse model ... that adding antioxidant therapy to traditional antimalarial treatment may ... were published online June 24, 2010, in the journal ... by parasites that invade liver and red blood cells, ...
... America (GSA) the nation,s largest interdisciplinary organization devoted ... Fung, PhD, of the Chinese University of Hong Kong ... Paul B. Baltes Foundation Award in Behavioral and Social ... early career contributions in behavioral and social gerontology. ...
... ENT and ... “Holes in My Shoes.” The film made its broadcast premier last Holiday Season on ... at 10pm. , ... (Vocus) June 25, 2010 -- ENT and Allergy Associates, LLP (ENTA) is proud to ...
Cached Medicine News:Health News:Chronic Pain Often Follows U.S. Soldiers Home: Study 2Health News:Chronic Pain Often Follows U.S. Soldiers Home: Study 3Health News:Mechanism that may trigger degenerative disease identified 2Health News:Antioxidants may help prevent malaria complicaton that leads to learning impairment 2Health News:Antioxidants may help prevent malaria complicaton that leads to learning impairment 3Health News:Fung to receive GSA's 2010 Baltes Foundation Award 2Health News:ENT and Allergy Associates Sponsors Award Winning PBS Documentary 2
The cardiac blanket is pre-positioned at the waist during prep, unrolled upon closure of the saphenous vein graft incision, and inflated post-bypass....
The adult blanket provides full coverage for patients of all sizes. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also reduces ...
The cath lab blanket, designed for use in the Cardiac Cath Lab, surrounds the patient with warm air and allows unrestricted access to the femoral artery....
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
Medicine Products: